Market Newsdesk

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) — Institutional investors holding positions in EOS Energy Enterprises, Inc. (NASDAQ: EOSE) during the period November 5, 2025 through February 26, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

EOSE shares fell $4.39 per share, a 39.4% single-day decline, on February 26, 2026 after the Company reported full year 2025 revenue of $114.2 million against previously affirmed guidance of $150 million to $160 million. The window to apply for lead plaintiff closes on May 5, 2026.

Fiduciary Obligations and Recovery Options

Fund managers and plan fiduciaries with EOSE holdings during the Class Period should assess whether participation in this action is consistent with their obligations to beneficiaries. The lawsuit asserts that between November 5, 2025 and February 26, 2026, the Company’s securities traded at artificially inflated prices due to alleged misrepresentations about manufacturing capacity and production readiness.

• Fiduciaries holding EOSE shares may have an obligation to evaluate recovery options on behalf of fund beneficiaries
• Serving as lead plaintiff allows institutional holders to select counsel, oversee litigation strategy, and protect beneficiary interests
• Lead plaintiff appointment carries no out-of-pocket cost to the institution or its beneficiaries
• Institutions with the largest financial interest in the recovery are typically appointed by the Court
• Passive class members retain the right to share in any recovery without serving as lead plaintiff
• Portfolio losses tied to the 39.4% single-day decline may be recoverable under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934

Contact us for institutional recovery options
or call (212) 363-7500.

Portfolio Impact Assessment

The complaint contends that EOSE reached a Class Period high of $19.19 on November 10, 2025, fueled by the Company’s assertions about production ramp progress and revenue guidance reaffirmation. The action claims that undisclosed manufacturing failures, including equipment downtime in the mid-30% range versus a 10% industry benchmark, rendered those representations materially misleading. Institutional portfolios that accumulated or held positions based on those representations may have absorbed significant losses when the corrective disclosure emerged.

“Institutional investors play a critical role in securities class actions. Their participation helps ensure vigorous representation of the entire class and that recovery efforts are conducted with the diligence and oversight that all shareholders deserve.” — Joseph E. Levi, Esq.

Case Summary

The securities action, filed in the United States District Court for the District of New Jersey, alleges that the Company and certain officers made materially false and misleading statements regarding production capabilities, automation progress, and fiscal year 2025 revenue guidance. As pleaded, these misrepresentations artificially inflated the price of EOSE securities throughout the Class Period, and the February 26, 2026 corrective disclosure caused substantial shareholder harm.

Request a confidential portfolio impact review
or contact Joseph E. Levi, Esq. at (212) 363-7500.

INSTITUTIONAL INVESTOR REPRESENTATION — Levi & Korsinsky, LLP provides sophisticated counsel to institutional investors evaluating lead plaintiff opportunities. The firm has recovered hundreds of millions of dollars. Ranked among ISS Top 50 for seven consecutive years.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

EVANSVILLE, Ind., April 13, 2026 (GLOBE NEWSWIRE) — Old National Bancorp (NASDAQ: ONB) today announced a strategic alignment of its Commercial Banking leadership structure to better match leadership roles and responsibilities with the capabilities, reach, and complexity of its commercial clients. As part of this updated structure, Chris Doyle has joined Old National as President of Commercial Banking, and John C. Thurston has been promoted to President of Corporate Banking.

“We are thrilled to welcome Chris to Old National, and we are equally excited to welcome John into an expanded leadership role,” said Old National Chairman and CEO Jim Ryan. “This new alignment not only allows us to fully leverage the strengths and experience of both leaders, it also reflects the growing scale of our Commercial business and our commitment to providing exceptional, highly individualized service to all our commercial clients.”

Additionally, Old National is further aligning key Treasury Management and Commercial middle office functions. Joe Wicklander, president of Treasury Solutions & Payments, will continue to lead Treasury Management, Merchant Services, and the Financial Institutions Group while also taking on responsibility for Old National’s Foreign Exchange (FX) business and building out FinTech and Liquidity solutions. Tim Kocher will transition from Chief Credit Strategy Officer to Chief Service Delivery Officer, providing leadership that strengthens service delivery for Commercial Banking clients.

These leadership updates follow the departure of Commercial Banking CEO Jim Sandgren, who retired on April 1, 2026, after 34 years of service with the organization.

About Chris Doyle

Old National welcomes Chris Doyle as President of Commercial Banking. Doyle brings more than 20 years of banking experience, most recently serving as Commercial Regional Leader, SVP, at a super-regional bank, where he spent nine years supporting complex client transactions, growth strategies, capital needs, and succession planning.

In this new leadership role, Doyle will oversee Commercial & Industrial (C&I) Banking (including SBA lending and Agricultural lending), Middle Market Banking (including Asset-Based Lending, Small Business Investment Company, and Family Office), Commercial Real Estate and Expansion Markets.

Doyle is active in the local Cleveland-area community where he serves as a board member of Urban Community School (Board Chair), Boys and Girls Clubs of Greater Cleveland, Cleveland Clinic Children’s Hospital, and GESU Finance Council. He is also a member of Leadership Cleveland class of 2026. Chris earned a Bachelor of Business Administration in Finance from Saint Louis University.

About John C. Thurston

John C. Thurston, who joined Old National in 2023 and most recently served as Corporate Banking Director, has been appointed President of the Corporate Bank, which will serve Old National’s largest commercial banking clients. Thurston brings 30 years of industry experience spanning multiple geographies, lines of business, and industry verticals.

He has led teams across the country while driving strategic initiatives, new business development, and long‑term client growth strategies. In his expanded leadership role, Thurston will oversee Corporate Banking, Specialty Banking, and Capital Markets (including Syndications, Tax Credit, Term Loan B, Sponsor Finance, and Investment Banking/M&A).

A resident of Chicago for more than 30 years, John is highly active in the Chicago community, serving as a member of the Board of Directors at Christ the King Jesuit College Prep, as well as a Board Member at Mercy Home for Boys and Girls. He is the past Chairman of the Old St. Mary’s Church Finance Committee, and a member of the Old St. Mary’s School Finance Sub-committee and Amate House Board of Directors. John earned a Bachelor of Business Administration and Bachelor of Arts in Finance and Business Economics from the University of Notre Dame.

About Joe Wicklander

As President of Treasury Solutions & Payments, Joe Wicklander has modernized and enhanced Old National’s Treasury Management and Merchant Services offerings while also launching a Financial Institutions Group. He will continue to lead Treasury Management, Merchant Services, and the Financial Institutions Group with added responsibility for Old National’s Foreign Exchange (FX) business. Prior to joining Old National in 2023, he led the Financial Institutions Group for CIBC Bank in Chicago.

About Tim Kocher
Tim Kocher will transition from Chief Credit Strategy Officer to Chief Service Delivery Officer, providing operational leadership that strengthens service delivery for Commercial Banking clients. In this role, he will oversee Commercial Administration (including loan fulfillment and commercial support) and Treasury Management middle office functions, helping ensure consistent execution, strong controls, and a seamless client experience. Formerly a member of Bremer Bank’s executive leadership team, Kocher officially transitioned to Old National’s leadership with the completion of the bank’s Bremer Bank partnership in 2025.

ABOUT OLD NATIONAL


Old National Bancorp (NASDAQ: ONB) is the holding company of Old National Bank. As the sixth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $72 billion of assets and $37 billion of assets under management, Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2025, Points of Light named Old National one of “The Civic 50” – an honor reserved for the 50 most community-minded companies in the United States.

Investor Relations:

Lynell Durchholz
(812) 464-1366
[email protected] 

Media Relations:

Rick Vach
(904) 535-9489
[email protected] 

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP alerts investors in Franklin BSP Realty Trust, Inc. (NYSE: FBRT) that three senior executives are named as individual defendants in a securities class action covering purchases between November 5, 2024 and February 11, 2026. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at [email protected] | (212) 363-7500.

FBRT shares fell $1.44 per share, or 14.18%, closing at $8.71 on February 12, 2026, after the Company disclosed a dividend cut from $0.355 to $0.20 per share. To be considered for lead plaintiff, investors must file by April 27, 2026.

The Named Individual Defendants

The action names the following officers as individual defendants under Section 20(a) of the Securities Exchange Act of 1934:

• Richard J. Byrne served as Chief Executive Officer until February 10, 2026, and as Chairman of the Board of Directors at all relevant times. The complaint contends Byrne directly participated in Company management and was privy to confidential information about FBRT’s dividend sustainability.
• Jerome S. Baglien served as Chief Financial Officer, Chief Operating Officer, and Treasurer throughout the Class Period. The lawsuit asserts Baglien was directly involved in drafting and disseminating the allegedly misleading statements about dividend coverage.
• Michael Comparato served as President until February 10, 2026, when he replaced Byrne as CEO. According to the action, Comparato ultimately disclosed on February 12, 2026 that REO liquidations had taken “longer than originally anticipated, keeping equity locked in underperforming investments.”

Section 20(a) Control Person Framework

The complaint charges that each Individual Defendant exercised control over FBRT’s public communications, including earnings call statements and press releases that repeatedly affirmed the $0.355 dividend level. As controlling persons, they are alleged to bear personal liability for the Company’s violations of Section 10(b) and Rule 10b-5.

Sarbanes-Oxley Certification Obligations

As CEO and CFO, the Individual Defendants were required under Sections 302 and 906 of the Sarbanes-Oxley Act to personally certify the accuracy of FBRT’s periodic SEC filings. The action alleges these certifications were made while the defendants knew or recklessly disregarded that:

• The $0.355 dividend was not supported by distributable earnings, which stood at only $0.27 per share as of Q2 2025
• REO resolution timelines were materially slower than represented to investors
• The Company was “over-distributing capital to investors” and eroding book value
• Capital redeployment projections used to justify maintaining the dividend lacked a reasonable basis

“Corporate officers have a duty to ensure their companies’ public statements are accurate and complete. When senior executives personally certify financial statements while allegedly aware that core representations about dividend sustainability lack support, investors deserve accountability.” — Joseph E. Levi, Esq.

Submit your information to join the recovery
or call Joseph E. Levi, Esq. at (212) 363-7500.

Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP encourages investors who suffered losses in Gartner, Inc. (NYSE: IT) to contact the firm. Those who purchased Gartner securities between February 4, 2025, and February 2, 2026, may be entitled to recover damages. Find out if you are eligible to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

Gartner shares fell from a Class Period high of $336.71 to $160.16, a cumulative loss of over 52%. Below is the chronology of material events shareholders need to understand.

February 4, 2025: Medium-Term Growth Targets Publicly Set

Management introduced fiscal 2025 guidance during the Q4 2024 earnings call, projecting Research CV growth would accelerate beyond the 7.8% Q4 exit rate, with a stated medium-term objective of 12% to 16%. The Company characterized its outlook as “achievable with opportunity for upside” and stated it had modeled CV growth “accelerating over the course of 2025.”

May 6, 2025: Q1 Results Show First Cracks

Gartner reported Q1 CV growth of 7%, with global CV actually declining $63 million sequentially from Q4 2024. Approximately 80% of that sequential drop was attributed to the U.S. federal government. The lawsuit contends that management downplayed this deterioration, reiterating medium-term 12% to 16% CV growth targets and characterizing results as “ahead of expectations.”

August 5, 2025: CV Growth Drops to 5%, Stock Falls 27.55%

The action alleges the first major corrective disclosure occurred here. CV growth decelerated from 7% to 5% overall, and from 8% to 6% excluding federal contracts. Shares plunged $92.78 in a single session, closing at $243.93.

Submit your claim before the deadline or call (212) 363-7500.

November 4, 2025: Defendants Allegedly Continued to Mislead

During the Q3 earnings call, the complaint alleges management claimed the tariff-affected selling environment had begun to “improve” and repeated assertions that CV growth would accelerate into 2026, while refusing to confirm any bottoming of the growth rate in Q4.

February 3, 2026: Full Truth Emerges

Gartner disclosed a further decline in CV growth, to only 1% overall, and down to 4% excluding federal contracts, and for the first time revealed a significant shortfall in Consulting segment performance against internal projections. Shares fell another 20.87%, or $42.24, to $160.16.

Chronology of Material Events

• Feb. 4, 2025: CV growth projected to accelerate from 7.8% toward 12%-16% medium-term target
• May 6, 2025: CV growth reported at 7%; global CV declined $63 million sequentially; 12%-16% target reiterated
• Aug. 5, 2025: CV growth fell to 5% (6% ex-federal); stock dropped 27.55% in one day
• Nov. 4, 2025: Management allegedly claimed selling environment was improving; reiterated 2026 acceleration, while CV growth fell to 3% (but held at 6% ex-federal)
• Feb. 3, 2026: CV growth fell to approximately 1% (4% ex-federal); Consulting shortfall disclosed for first time; stock dropped 20.87%

“Timely disclosure of material developments is fundamental to fair and efficient markets. The chronology here raises questions about the widening gap between management’s repeated assurances and the trajectory investors ultimately experienced.” — Joseph E. Levi, Esq.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years. Those wishing to serve as lead plaintiff must act by May 18, 2026.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP encourages investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) to contact the firm.

WHO IS AFFECTED: Those who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 may be entitled to recover damages. Find out if you are eligible to recover losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

IBRX shares lost $1.98 per share, a 21% decline, closing at $7.42 on March 24, 2026, after an FDA Warning Letter exposed allegedly false promotional claims. The window to apply for lead plaintiff closes on May 26, 2026.

January 19, 2026: The Podcast That Triggered Regulatory Scrutiny

The class period opens on the date ImmunityBio’s Executive Chairman appeared on The Sean Spicer Show podcast and made sweeping claims about ANKTIVA, the Company’s lead biologic product. According to the lawsuit, the broadcast suggested that ANKTIVA could treat “all cancers,” was represented as a “cancer vaccine,” and was characterized as a simple subcutaneous injection. The podcast was linked on the Company’s corporate website, amplifying its reach to investors and patients.

January 19, 2026 through March 12, 2026: The Period of Alleged Artificial Inflation

During these weeks, the action contends that IBRX shares traded at artificially inflated prices. Investors purchased stock without knowledge that the promotional claims allegedly violated federal drug promotion regulations. ANKTIVA was approved solely for a specific type of bladder cancer. According to the complaint, bladder cancers represented only an estimated 4.2% of new cancer cases in 2025. The drug’s efficacy was established only in combination with BCG, and a cohort studying ANKTIVA as a single agent was stopped early for futility.

March 13, 2026: The FDA Warning Letter Is Issued

The FDA’s Office of Prescription Drug Promotion issued a Warning Letter to ImmunityBio’s CEO at the Company’s Culver City, California facility. The letter determined that both a TV advertisement and the January podcast were “false or misleading” and that the promotional materials misbranded ANKTIVA in violation of the Federal Food, Drug, and Cosmetic Act. The FDA characterized the claims as “especially concerning from a public health perspective.”

March 24, 2026: The Corrective Disclosure Reaches Investors

The Warning Letter was publicized, and Bloomberg reported the story under the headline “ImmunityBio Plunges After Getting FDA Warning on Cancer Drug.” IBRX shares fell 21% in a single session. The Company subsequently removed the podcast from its website.

Timeline of Alleged Disclosure Failures

• January 19, 2026: Podcast broadcast with claims ANKTIVA could treat “all cancers” and prevent cancer from radiation exposure
• January 19, 2026: On-screen graphic labeled ANKTIVA a “Cancer Therapeutic Vaccine (BioShield)”
• January 19, 2026 onward: Podcast linked on Company website, accessible to investors and patients
• March 13, 2026: FDA Warning Letter issued, citing false and misleading promotional communications
• March 24, 2026: Warning Letter publicized; IBRX shares declined 21% to $7.42
• Post-disclosure: Company removed podcast from its website

Submit your claim before the deadline or call Joseph E. Levi, Esq. at (212) 363-7500.

“Timely disclosure of material developments is fundamental to fair and efficient markets. The chronology in this case raises questions about why investors were not alerted to regulatory risks sooner.” — Joseph E. Levi, Esq.

About Levi & Korsinsky, LLP

For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years. Those wishing to serve as lead plaintiff must act by May 26, 2026.

Frequently Asked Questions About the IBRX Lawsuit

Q: When did ImmunityBio allegedly mislead investors? A: The class period runs from January 19, 2026 to March 24, 2026. The alleged fraud was revealed through the publicization of an FDA Warning Letter, causing a significant stock decline of 21%.

Q: How much did IBRX stock drop? A: Shares fell approximately 21%, a decline of $1.98 per share, after the FDA Warning Letter was publicized on March 24, 2026. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.

Q: What do IBRX investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my IBRX shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that it has received a highly contingent, non-binding and unsolicited proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) to acquire all of the outstanding shares of Seer’s Class A common stock for $2.25 per share in cash plus a contingent value right (the “Proposal”).

Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Seer Board of Directors (the “Board”) will carefully review and consider the Proposal to determine the course of action that it believes is in the best interests of the Company and all Seer stockholders.

In addition, Radoff-JEC Group has nominated three director candidates to stand for election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The Corporate Governance and Nominating Committee of the Board will review the proposed nominees in accordance with the Company’s bylaws.

The Board will present its formal recommendation regarding the Radoff-JEC Group’s director nominations in the Company’s definitive proxy statement, to be filed with the Securities and Exchange Commission and mailed to all stockholders eligible to vote at the 2026 Annual Meeting. The date of the 2026 Annual Meeting has not yet been announced.

No stockholder action is required at this time.

Perella Weinberg Partners LP is serving as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph^® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at [email protected].

Additional Information and Where to Find It

Seer, its directors and certain executive officers are participants in the solicitation of proxies from stockholders in connection with Seer’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Seer plans to file a proxy statement (the “2026 Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies for the Annual Meeting.

Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Deep Nishar, Isaac Ro and Nicolas Roelofs, all of whom are members of Seer’s board of directors, and David Horn, Seer’s president and chief financial officer, are participants in Seer’s solicitation. Additional information regarding such participants, including their direct or indirect interests, by security holdings or otherwise, will be included in the 2026 Proxy Statement and other relevant documents to be filed by Seer with the SEC in connection with the Annual Meeting. Information relating to the foregoing can also be found in Seer’s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the “2025 Proxy Statement”), which was filed with the SEC on May 28, 2025, and is available here. Particular attention is directed to the sections of the 2025 Proxy Statement captioned “Board of Directors and Corporate Governance,” “Executive Compensation,” “Named Executive Officer Compensation Overview,” “Security Ownership of Certain Beneficial Owners and Management” and “Certain Relationships, Related Party and Other Transactions.” To the extent that holdings of such participants in Seer’s securities have changed since the amounts printed in the 2025 Proxy Statement, such changes have been reflected on the following filings: for Mr. Farokhzad, on May 22, 2025, August 21, 2025, November 21, 2025, December 11, 2025, February 5, 2026, and February 19, 2026; for Ms. Gulyani, on July 9, 2025; for Mr. Langer, on July 9, 2025; for Mr. McGuire, on July 9, 2025 and December 11, 2025; for Mr. Nishar, on June 16, 2025 and July 9, 2025; for Mr. Ro, on September 3, 2025; for Mr. Roelofs, on July 9, 2025; and for Mr. Horn, on May 22, 2025; August 21, 2025; November 21, 2025, February 5, 2026, and February 19, 2026.

Promptly after filing its definitive 2026 Proxy Statement with the SEC, Seer will mail the definitive 2026 Proxy Statement and a BLUE proxy card to each stockholder entitled to vote at the Annual Meeting. STOCKHOLDERS ARE URGED TO READ THE 2026 PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT SEER WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, Seer’s proxy statement (in both preliminary and definitive form), any amendments or supplements thereto, and any other relevant documents filed by Seer with the SEC in connection with the Annual Meeting at the SEC’s website, which is located here. Copies of Seer’s definitive 2026 Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by Seer with the SEC in connection with the Annual Meeting will also be available, free of charge, at Seer’s website, which is located here, or by writing to Investor Relations, Seer, Inc., 3800 Bridge Parkway, Suite 102, Redwood City, CA 94065.

Forward Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions to be taken by the Board. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:

Patrick Schmidt
[email protected]

Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449

Investor Contact:

Marissa Bych
[email protected]